Working With Peptide Blends: Reconstitution Math for BPC-157 + TB-500

Combination peptide vials — formulated with two or more peptides co-lyophilized in a single container — are increasingly common in research workflows where comparative or synergistic in vitro and animal-model studies are planned. Reconstitution math for blends requires explicit accounting of each constituent’s concentration, since dose-response analyses depend on knowing the exact amount of each peptide delivered per aliquot.

Reading the vial label. A typical research blend vial label will state total peptide mass and the ratio or individual masses of the constituents. For example, a 10 mg BPC-157 + TB-500 blend may contain 5 mg BPC-157 and 5 mg TB-500, or alternative ratios such as 4 mg BPC + 6 mg TB. Always confirm the breakdown on the accompanying certificate of analysis (COA) [1].

Concentration math example. Reconstituting a 10 mg total blend (5 mg BPC-157 + 5 mg TB-500) with 2 mL of bacteriostatic water yields: – Total peptide concentration: 5 mg/mL – BPC-157 concentration: 2.5 mg/mL – TB-500 concentration: 2.5 mg/mL

A 100 µL aliquot therefore delivers 250 µg of each peptide. For experimental designs comparing individual peptides to the blend, the equivalent single-peptide dose is the individual peptide concentration — not the total peptide concentration.

Solubility considerations. Both BPC-157 and TB-500 are highly water-soluble at physiological pH, and the blend reconstitutes cleanly in bacteriostatic or sterile water [2]. Blends combining a hydrophilic and a hydrophobic peptide require pre-formulation review of the COA for any solubilizing excipients.

Documentation and traceability. Record the lot number, reconstitution date, diluent type, and final concentration on the vial label and in the laboratory notebook. Co-formulated blends complicate post-hoc analysis if the individual contributions are not documented at the bench [3].

For research workflows requiring co-formulated peptides, Frontier Peptide Labs’ BPC-157 + TB-500 Blend Vial (10 mg) ships lyophilized with a COA detailing the individual peptide masses, for laboratory research use only.

References

1. Manning MC, et al. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. DOI: 10.1007/s11095-009-0045-6
2. Vlieghe P, et al. Synthetic therapeutic peptides: science and market. Drug Discov Today. 2010;15(1-2):40-56. DOI: 10.1016/j.drudis.2009.10.009
3. Carpenter JF, et al. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol. 1999;309:236-55. DOI: 10.1016/s0076-6879(99)09018-7